Kodiak Sciences Inc. (Nasdaq: KOD) today announced that it has completed enrollment of the first 300-patient cohort in its PEAK trial, supporting Pivotal Analysis 1 of the KSI-101 Phase 3 program in ...
The optic cup and macula of a 24-year-old female. Image is released to Wikimedia commons with patient consent. Imaged with a non-mydriatic fundus camera at Pacific University College of Optometry.
Diabetic macular edema (DME) is an eye condition that can lead to vision loss in people with diabetes. It occurs as a result of diabetic retinopathy — damaged blood vessels in the eyes due to elevated ...
Uveitic macular edema has been investigated by many research groups, who reported their results at the 2012 annual meeting of the Association for Research in Vision and Ophthalmology (ARVO). These ...
Planned IND submission for SZN-8141 in diabetic macular edema by the end of the third quarter of 2026Expect to initiate SZN-8141 Phase 1b/2a ...
In Mexico, at least 14 million people have developed macular edema due to diabetes (DME), which like retinopathy affects central vision and can lead to blindness if not treated early . "There are no ...
CV, a Phase 2 dose-ranging proof-of-concept trial of BGE-102 measuring inflammatory and cardiometabolic biomarkers; topline data anticipated in the second half of 2026 QUELL-DME, Phase 1b/2a ...
BARCELONA, Spain — Treating type 2 diabetic patients with pioglitazone significantly increases the risk for macular edema, according to the results of a new Japanese study. For those who received the ...
W hen diagnosed with diabetic macular edema (DME) in 2017, Sarah Castaneda, 41, thought she would lose her eyesight completely. At least, that’s what her doctor told her would happen if she didn’t ...
This story is part of a series on the current progression in Regenerative Medicine. This piece is part of a series dedicated to the eye and improvements in restoring vision. In 1999, I defined ...
Nicholas G. Anderson, MD, and Philip Niles, MD, MBA, provide an overview of diabetic macular edema (DME) and the impact of vision impairment on a patient’s quality of life. Jim Kenney, RPh, MBA: Dr.